Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan has received a license from the European Commission to market Ganfort, a Lumigan/timolol combination product for the treatment of glaucoma, in the European Union.
Subscribe to our email newsletter
Ganfort (bimatoprost/timolol ophthalmic solution) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
A fixed combination of bimatoprost 0.03% and timolol maleate 0.5%, Ganfort offers powerful IOP-lowering efficacy comparable to the free combination of these two agents, and greater efficacy than monotherapy with either agent used alone. Ganfort also provides clinically important IOP control in a once-daily dose, which is important for enhancing patient compliance – a key factor in controlling glaucoma.
In clinical trials, Ganfort also had a superior tolerability profile, including 40% less hyperemia compared to bimatoprost monotherapy.